1-3 of 3
Robin Guild
Close
Sort by
Journal Articles

Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

Jesus G. Berdeja, MD, Francisco Hernandez-Ilizaliturri, MD, Asher Chanan-Khan, MD, Manish Patel, MD, Kevin R. Kelly, MD, Kelli L. Running, Mary Murphy, Robin Guild, Christina Carrigan, PhD, Sharron Ladd, Beni B. Wolf, MD, PhD, James J. O'Leary, MD, Sikander Ailawadhi, MD
Journal: Blood
Blood (2012) 120 (21): 728.
https://doi.org/10.1182/blood.V120.21.728.728
Published: 2012
Journal Articles

Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis.

Asher Chanan-Khan, MD, Jeffrey Wolf, MD, Mecide Gharibo, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Debbie Manfredi, Kelvin P. Lee, MD, Kena C Miller, NP, Robin Guild, Sybil Zildjian, MPH, Albert Qin, MD, Ph.D., James O'Leary, MD, Robert Vescio, MD
Journal: Blood
Blood (2009) 114 (22): 2883.
https://doi.org/10.1182/blood.V114.22.2883.2883
Published: 2009
Journal Articles

Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma

Asher Alban Chanan-Khan, MD, Mecide Gharibo, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Kenneth C Anderson, MD, Dawn DePaolo, Kelvin P. Lee, MD, Kena Miller, RN, MSN, FNP, Robin Guild, Sybil Zildjian, Albert Qin
Journal: Blood
Blood (2008) 112 (11): 3689.
https://doi.org/10.1182/blood.V112.11.3689.3689
Published: 2008